NERRE THERAPEUTICS HOLDINGS LIMITED

Active Stevenage

Research and experimental development on biotechnology

0 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
N

NERRE THERAPEUTICS HOLDINGS LIMITED

Research and experimental development on biotechnology

Founded 3 May 2017 Active Stevenage, United Kingdom 0 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 26 Feb 2026 Next due 31 Mar 2026 26 days overdue
Confirmation Submitted 10 Mar 2026 Next due 12 Mar 2027 10 months remaining
Net assets £-18M £43M 2025 year on year
Total assets £830K £40M 2025 year on year
Total Liabilities £19M £3M 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Stevenage Bioscience Catalyst, Incubator Building Gunnels Wood Road Stevenage Hertfordshire SG1 2FX United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for NERRE THERAPEUTICS HOLDINGS LIMITED (10753026), an active life sciences and medical technology company based in Stevenage, United Kingdom. Incorporated 3 May 2017. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2025
Type Total Exemption Full
Next accounts 31 December 2026
Due by 30 September 2027 9 months

Net Assets, Total Assets & Total Liabilities (2018–2025)

Cash in Bank

£80.26k

Decreased by £8.02k (-9%)

Net Assets

-£18.25M

Decreased by £42.74M (-175%)

Total Liabilities

£19.08M

Increased by £3.03M (+19%)

Turnover

N/A

Employees

N/A

Debt Ratio

2299%

Increased by 2259 (+5648%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
Dec Year End
2024
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (10)

Investor NameInvestor SinceParticipating Rounds
Investor 8Dec 2012Series A
Investor 9Dec 2012Series A
Investor 10Dec 2012Series A

Share Capital

Share Capital

Share allotments and capital structure

10 Allotments 6,293,613 Shares £4.81m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
5 Sept 2025128,700£6.435£0
22 Jul 20251,056,401£52.83£52.83
27 Jun 20245,000£0.25£0
5 Sept 2023218,179£10.909£0
23 Jun 2022238,600£2.85m£11.93

Officers

Officers

2 active 1 resigned
Status
García Cogorro, JavierDirectorSpanishSpain6325 Jun 2021Active
Mulder, Geert Jan, DrDirectorDutchNetherlands598 Sept 2017Active

Shareholders

Shareholders (41)

Uk Ff Nominees Limited
12.3%
9,044,909
Forbion Capital Fund Iii Cooperatief Ua
11.8%
8,718,602

Persons with Significant Control

Persons with Significant Control (0)

0 Active 2 Ceased

Advent Life Sciences Llp

Ceased 25 Jun 2021

Ceased

Michael Keith Trower

Ceased 8 Sept 2017

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
31 Mar 2026OfficersTermination of Andrew Martin Kay as director on 2026-03-31
10 Mar 2026Confirmation StatementConfirmation statement made on 2026-02-26 with updates
26 Feb 2026AccountsAnnual accounts made up to 2025-06-30
18 Feb 2026OfficersChange to director Dr Iain David Dukes on 2026-02-17
18 Feb 2026OfficersChange to director Dr Ena Prosser on 2026-02-18
31 Mar 2026 Officers

Termination of Andrew Martin Kay as director on 2026-03-31

10 Mar 2026 Confirmation Statement

Confirmation statement made on 2026-02-26 with updates

26 Feb 2026 Accounts

Annual accounts made up to 2025-06-30

18 Feb 2026 Officers

Change to director Dr Iain David Dukes on 2026-02-17

18 Feb 2026 Officers

Change to director Dr Ena Prosser on 2026-02-18

Recent Activity

Latest Activity

Termination of Andrew Martin Kay as director on 2026-03-31

3 weeks ago on 31 Mar 2026

Confirmation statement made on 2026-02-26 with updates

1 months ago on 10 Mar 2026

Annual accounts made up to 2025-06-30

1 months ago on 26 Feb 2026

Change to director Dr Iain David Dukes on 2026-02-17

2 months ago on 18 Feb 2026

Change to director Dr Ena Prosser on 2026-02-18

2 months ago on 18 Feb 2026